Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus

Abstract

The Absorb diabetic substudy suggests efficacy and safety of the Absorb BVS for treatment of patients with diabetes mellitus.

Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST‐EURegistry

“…On the other hand, the increased vessel inflammation distinctive of patients with DM may have a less favorable impact on the early clinical outcomes associated with BRS use in this high‐risk subset. However, little is known on the mid‐term clinical safety and efficacy after BRS treatment in an all‐comers population with DM treated under real‐world conditions .…”

“…The efficacy and safety of Absorb BVS in DM patients was assessed in a recent study including 754 patients pooled from three randomized trials (ABSORB II, III, and JAPAN) and from the single arm ABSORB EXTEND registry . Rates of 1‐year TLF and definite/probable scaffolds thrombosis reported in this latter analysis were 8.3% and 2.3%, respectively.…”

“…Interestingly, the 10.9% TLF rate of patients with DM and a small vessel treated was similar to the rate reported among the DM subgroup in the ABSORB III trial , in which the mean RVD of the overall population was small (2.67 ± 0.45 mm). In addition, smaller preprocedure RVD emerged as significant independent predictor of 1‐year TLF among the population with DM enrolled in the ABSORB randomized clinical trials . Based on the ABSORB III trial results, recently the FDA approved Absorb BVS for patients having a narrowing in their coronary artery lesions that is less than or equal to 24 mm long with a RVD of ≥ 2.5 mm and ≤ 3.75 mm.…”

“…The Absorb BVS studies have enrolled relevant proportions of patients with DM; in addition, DM has emerged as an independent predictor of device‐related ischemic events after BVS implantation . However, dedicated analyses focusing on the BVS performance in diabetes patients compared with those without DM derived from more complex and unselected populations treated under real‐world conditions are limited . The present study was a subanalysis of the GHOST‐EU registry aiming to report clinical outcomes associated with Absorb BVS use in diabetes patients and to compare them with those in nondiabetes patients among an all‐comers population.…”

Percutaneous coronary intervention for patients with type 2 diabetes mellitus: risks and novel way to manage

“…Исследование, посвященное оценке исходов ЧКВ при при-менении биорезорбируемых стентов Absorb, показало эффективность и безопасность применения указанных стентов у пациентов с известным СД. Вместе с тем получены данные о том, что возраст, инсулинотерапия и малый диаметр сосуда ассоциированы со значимо более высокой частотой развития основных неблагоприятных сердечно-сосудистых событий (Major Adverse Cardiac Events -MACE), особенно ИМ в течение 1 года [30]. Принимая во внимание тот факт, что у лиц с СД малый диаметр коронарных сосудов является характерной особенностью, можно предположить, что применение биорезорбируемых стентов требует дальнейшего изучения.…”